Related Experiment Video
Updated: Oct 26, 2025

Selection-dependent and Independent Generation of CRISPR/Cas9-mediated Gene Knockouts in Mammalian Cells
Published on: June 16, 2017
A Transposon-Associated CRISPR/Cas9 System Specifically Eliminates both Chromosomal and Plasmid-Borne mcr-1 in
Yu-Zhang He1,2,3,4, Jin-Ru Yan1,2,3, Bing He1,2,3
1National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Abstract:
The global spread of antimicrobial-resistant bacteria has been one of the most severe threats to public health. The emergence of the mcr-1 gene has posed a considerable threat to antimicrobial medication since it deactivates one last-resort antibiotic, colistin. There have been reports regarding the mobilization of the mcr-1 gene facilitated by ISApl1-formed transposon Tn6330 and mediated rapid dispersion among Enterobacteriaceae species. Here, we developed a CRISPR/Cas9 system flanked by ISApl1 in a suicide plasmid capable of exerting sequence-specific curing against the mcr-1-bearing plasmid and killing the strain with chromosome-borne mcr-1. The constructed ISApl1-carried CRISPR/Cas9 system either restored sensitivity to colistin in strains with plasmid-borne mcr-1 or directly eradicated the bacteria harboring chromosome-borne mcr-1 by introducing an exogenous CRISPR/Cas9 targeting the mcr-1 gene. This method is highly efficient in removing the mcr-1 gene from Escherichia coli, thereby resensitizing these strains to colistin. The further results demonstrated that it conferred the recipient bacteria with immunity against the acquisition of the exogenous mcr-1 containing the plasmid. The data from the current study highlighted the potential of the transposon-associated CRISPR/Cas9 system to serve as a therapeutic approach to control the dissemination of mcr-1 resistance among clinical pathogens.
Insights
A novel CRISPR/Cas9 system effectively eliminates the mcr-1 gene, a colistin resistance factor, from bacteria. This approach restores colistin sensitivity and prevents further spread of antimicrobial resistance.
Area of Science:
- Microbiology
- Genetics
- Molecular Biology
Background:
- Antimicrobial resistance, particularly to last-resort antibiotics like colistin, is a major global public health threat.
- The mcr-1 gene, conferring colistin resistance, is rapidly spreading among Enterobacteriaceae species, often facilitated by mobile genetic elements like transposons.
- Existing treatments are becoming less effective against resistant bacterial strains.
Purpose of the Study:
- To develop a targeted gene-editing strategy to eliminate the mcr-1 gene from bacteria.
- To assess the efficacy of a CRISPR/Cas9 system in combating colistin resistance.
- To investigate the potential of this system as a therapeutic approach against antimicrobial resistance.
Main Methods:
- Development of a suicide plasmid carrying an ISApl1-flanked CRISPR/Cas9 system.
- Application of the system to target and eliminate both plasmid-borne and chromosome-borne mcr-1 genes.
- Evaluation of bacterial sensitivity to colistin post-treatment.
- Assessment of immunity against exogenous mcr-1 acquisition.
Main Results:
- The CRISPR/Cas9 system successfully removed the mcr-1 gene from Escherichia coli, restoring colistin sensitivity.
- The system demonstrated efficacy against both plasmid-mediated and chromosomally-located mcr-1.
- Treated bacteria exhibited resistance to acquiring new mcr-1 genes via plasmids.
- High efficiency in gene curing and bacterial eradication was observed.
Conclusions:
- The transposon-associated CRISPR/Cas9 system is a potent tool for eradicating the mcr-1 gene.
- This technology offers a promising therapeutic strategy to combat colistin resistance and control the spread of antimicrobial resistance in clinical settings.
Related Concept Videos
CRISPR/Cas9 Genome Editing
CRISPR
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The Antiviral System of Bacteria and Archaea: CRISPR

